InvestorsHub Logo
Followers 22
Posts 4029
Boards Moderated 0
Alias Born 10/12/2013

Re: dmlcento post# 102682

Thursday, 03/16/2017 7:09:24 PM

Thursday, March 16, 2017 7:09:24 PM

Post# of 426435

My fear is that even with 25-35% RRR,


Those snivel from the wrong people are coming though. My fear is that even with 25-35% RRR, the likes of Adam Fartstain, Matt Herpes and Larry Husten, who are no fans of AMRN's "fish oil", will pick at every little thing to make the results seem inconsequential. And the unfortunate part is people will listen to those jerk




I discount that in large part. You've named stock investment guys. With a successful Reduce It, Amarin will be selling V to the docs and to the public. Again, wander through the fish oil section of Costco and ask yourself, "Have these investment guys damped demand for fish squeezings significantly by disparaging 'fish oil'?" With serious promotion backed by a solid study, V sales ramping will drive share prices up.

Adam, Matt, and Larry are discouraging sales of shares. Rising share prices on the backs of sales would drown them out.

There will be sniveling. If everything is done right and bolted down, it may be about subgroup vs subgroup or whether or not the study can be broadly applied beyond the narrow confines of the experimental group, or if Eastern Europe diabetic genetics and health care particulars can support generalization to a South Sea or South American population; par for the course and answerable with a caveat, follow up study, or looking the other way...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News